Zetagen Therapeutics

Zetagen Therapeutics is a clinical-stage biopharmaceutical company dedicated to driving breakthrough innovations in the treatment of bone and other organ metastatic cancers, as well as in bone-related predictions. Zetagen Therapeutics recently acquired intellectual property directly related to the development of ZetaMAST, a formulation designed for intratumoral injection in soft tissue organs such as the liver, lungs, and/or brain. Its pipeline includes further oncology solutions targeting metastatic prostate cancer and addressing skeletal-related events (SREs).